Pharmaceutical Executive Daily: what it takes to move machine learning.

{
  "signal_id": "1713b677-1c15-4bc9-8168-553bab984d1a",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-05-21T00:00:00+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "url": "https://www.pharmexec.com/view/daily-what-takes-move-machine-learning",
    "title": "Pharmaceutical Executive Daily: what it takes to move machine learning.",
    "ticker": "NASDAQ:GILD",
    "excerpt": "Pharmaceutical Executive Daily: what it takes to move machine learning.\n\nIn today's Pharmaceutical Executive Daily, Reuters reports that lower-priced oral GLP-1 pills from Eli Lilly and Novo Nordisk are drawing patients away from compounded weight loss medications, Gilead Sciences' renews its five-year collaboration with WHO and Johnson and Johnson's collaboration with the Department of Health Abu Dhabi, finally Partha Anbil argues that truly industrializing machine learning and AI in life sciences requires systems that are scientifically credible, clinically defensible, regulatorily traceable, and operationally sustained.\n\nWelcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.\n\nIn today's Pharmaceutical Executive Daily, Reuters reports that lower-priced oral GLP-1 pills from Eli Lilly and Novo Nordisk are drawing patients away from compounded weight loss medications, Gilead Sciences' renews its five-year collaboration with WHO and Johnson and Johnson's collaboration with the Department of Health Abu Dhabi, finally Partha Anbil argues that truly industrializing machine learning and AI in life sciences requires systems that are scientifically credible, clinically defensible, regulatorily traceable, and operationally sustained.\n\nDoctors interviewed by Reuters are reporting a in patient behavior as...",
    "summary": "Gilead Sciences partnered with World Health Organization International on May 22nd '26.",
    "location": "United Kingdom, Northern Europe, Europe",
    "planning": false,
    "image_url": "https://cdn.sanity.io/images/0vv8moc6/pharmexec/69ad66ff9a88b963b53a43ee2436f89da07d52ad-1280x720.jpg",
    "confidence": 0.3903,
    "published_at": "2026-05-22T00:28:00Z",
    "location_data": [
      {
        "region": "Northern Europe",
        "country": "United Kingdom",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-05-22",
    "article_sentence": "In today's Pharmaceutical Executive Daily, Reuters reports that lower-priced oral GLP-1 pills from Eli Lilly and Novo Nordisk are drawing patients away from compounded weight loss medications, Gilead Sciences' renews its five-year collaboration with WHO and Johnson and Johnson's collaboration with the Department of Health Abu Dhabi, finally Partha Anbil argues that truly industrializing machine learning and AI in life sciences requires systems that are scientifically credible, clinically defensible, regulatorily traceable, and operationally sustained.",
    "amount_normalized": 20000000,
    "related_company_name": "World Health Organization International",
    "related_company_domain": "who.int"
  }
}

curl https://signals.autobound.ai/v1/signals/1713b677-1c15-4bc9-8168-553bab984d1a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"gilead.com","limit":20}'